---
title: "Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)"
nct_id: NCT05372302
overall_status: UNKNOWN
sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
study_type: OBSERVATIONAL
primary_condition: Collecting Duct Carcinoma
countries: Italy
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05372302.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05372302"
ct_last_update_post_date: 2022-05-12
last_seen_at: "2026-05-12T07:11:11.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)

**NCT ID:** [NCT05372302](https://clinicaltrials.gov/study/NCT05372302)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Conditions:** Collecting Duct Carcinoma
- **Start Date:** 2021-07-08
- **Completion Date:** 2022-10
- **CT.gov Last Update:** 2022-05-12

## Brief Summary

* Collect a large number of samples with certain / suspected diagnosis of collecting duct carcinoma in order to confirm the diagnosis (centralized review) and standardize according to WHO 2016 criteria
* Build an extensive tissue bank (DNA and RNA extraction) aimed at defining the molecular taxonomy of the tumor through 1) transcriptomic analysis 2) gene expression profile
* Define specific molecular signatures

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age ≥ 18 years
* Signature of consent (for patients enrolled in the prospective part of the study)
* Histological diagnosis of renal cell carcinoma of the Bellini collecting duct RCC

Exclusion Criteria:

\-
```

## Primary Outcomes

- **samples to confirm and standardize** _(time frame: 15 month)_ — Collect a large number of samples with certain / suspected diagnosis of collecting duct carcinoma in order to confirm the diagnosis (centralized review) and standardize it according to WHO 2016 criteria

## Secondary Outcomes

- **Tissue Bank** _(time frame: 15 month)_
- **specific molecular signatures** _(time frame: 15 month)_

## Locations (1)

- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.fondazione irccs istituto nazionale tumori|milan||italy` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05372302.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05372302*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*